183 related articles for article (PubMed ID: 11341128)
1. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia.
Türkeri LN; Ozyürek M; Ersev D; Akdaş A
Arch Esp Urol; 2001 Mar; 54(2):191-6. PubMed ID: 11341128
[TBL] [Abstract][Full Text] [Related]
2. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
3. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
5. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
Roehrborn CG; Prajsner A; Kirby R; Andersen M; Quinn S; Mallen S
Eur Urol; 2005 Sep; 48(3):445-52; discussion 452. PubMed ID: 15996811
[TBL] [Abstract][Full Text] [Related]
6. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Chung BH; Hong SJ; Lee MS
Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia.
MacDiarmid SA; Emery RT; Ferguson SF; McGuirt-Franklin R; McIntyre WJ; Johnson DE
J Urol; 1999 Nov; 162(5):1629-32. PubMed ID: 10524884
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
Kirby RS; O'Leary MP; Carson C
BJU Int; 2005 Jan; 95(1):103-9; discussion 109. PubMed ID: 15638905
[TBL] [Abstract][Full Text] [Related]
9. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Siegel RL
Urology; 1996 Sep; 48(3):406-15. PubMed ID: 8804494
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
[TBL] [Abstract][Full Text] [Related]
12. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
[TBL] [Abstract][Full Text] [Related]
13. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
Gillenwater JY; Conn RL; Chrysant SG; Roy J; Gaffney M; Ice K; Dias N
J Urol; 1995 Jul; 154(1):110-15. PubMed ID: 7539854
[TBL] [Abstract][Full Text] [Related]
14. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
16. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
18. Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia.
Zhang Y; Wang Y; Zhang P; Zhang XD; Yang Y
Transplant Proc; 2009 Nov; 41(9):3747-51. PubMed ID: 19917379
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
